Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

Research output: Contribution to journalReview articlepeer-review

Abstract

Genetic alterations and epigenetic dysregulation in cancer cells create a vast array of neoepitopes potentially recognizable by the immune system. Immune checkpoint blockade has the capacity to enhance and sustain endogenous immunity against non-mutated tumor-associated antigens as well as uniquely mutant antigens, establishing durable tumor control. Recent evidence from preclinical models highlights the pivotal role of the Programmed Death-1 (PD-1) T cell co-receptor and its ligands, B7-H1/PD-L1 and B7-DC/PD-L2, in maintaining an immunosuppressive tumor microenvironment. Encouraging early clinical results using blocking agents against components of the PD-1 pathway have validated its importance as a target for cancer immunotherapy.

Original languageEnglish (US)
Pages (from-to)207-212
Number of pages6
JournalCurrent Opinion in Immunology
Volume24
Issue number2
DOIs
StatePublished - Apr 2012

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity'. Together they form a unique fingerprint.

Cite this